Clinical Trials Logo

Clinical Trial Summary

New/direct oral anticoagulants (NOAC/DOAC), like apixaban and rivaroxaban, are an interesting alternative to unfractionated or low molecular weight heparin relayed by oral anti-vitamin K anticoagulants (VKA) for the treatment of venous thromboembolism and atrial fibrillation. This new generation of anticoagulants directly inhibit a factor in the blood coagulation pathway and have a wide therapeutic range overcoming several practical issues associated with VKA therapy including the need of routine coagulation monitoring potentially simplifying patient management. However, despite this wide therapeutic range, a large interindividual dose variability related to factors such as age, body surface, smoking, concomitant diseases as well as differences in drug metabolism, could put susceptible patients at risk for uncontrolled bleeding. Both rivaroxaban and apixaban are cleared primarily via cytochrome P450 (CYP) mediated hepatic metabolism, mainly CYP3A, and renal excretion, involving the P-glycoprotein (P-gp). Both CYP3A and P-gp activity show important interindividual variations due to drug interactions and/or genetic polymorphisms in corresponding genes. The aim of the current study is to evaluate the impact of cytochrome activity and relevant polymorphisms on rivaroxaban/apixaban dosage regimen or treatment efficacy in a hospital setting. The safety issue in this context is particularly relevant, since hospitalisation is linked to a modification of the patient's treatment with often an increase in the number of medications. The resulting changes in metabolism due to modified cytochrome and transporter activities could affect rivaroxaban/apixaban blood concentrations. Our central hypothesis is that genotype and/or phenotype in CYP3A4/5/7 or P-gp may influence the rivaroxaban/apixaban plasma concentration and increase the risk of thrombotic or hemorrhagic events. Thus, investigating how the patient's genotype and/or phenotype for CYP3A4/5/7 and P-gp could potentially alter the bio-disponibility of rivaroxaban and apixaban and therefore the risk to develop adverse events or inefficacy would be of particular interest.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03112525
Study type Observational
Source University Hospital, Geneva
Contact
Status Completed
Phase
Start date June 28, 2017
Completion date January 7, 2021

See also
  Status Clinical Trial Phase
Completed NCT04517461 - Coagulation and Vitamin K in Head and Neck Microvascular Free Flap Surgery
Terminated NCT03296033 - Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Phase 4
Recruiting NCT05123326 - Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Completed NCT04074980 - Evaluation of the Accuracy of INR Results From Patients Taking Phenprocoumon as Anticoagulant When Measured Using the Lumiradx INR Test N/A
Completed NCT04505475 - Oral Surgery in Patients Taking Direct Oral Anticoagulants
Not yet recruiting NCT05997914 - Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation N/A
Recruiting NCT04329390 - MAC Project, Monitoring of AntiCoagulant Therapies (MAC)
Recruiting NCT03760874 - Atrial Fibrillation Research Database
Recruiting NCT04046029 - Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention. Phase 4
Completed NCT04444700 - A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic Phase 3
Terminated NCT03566303 - Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis Phase 2/Phase 3
Not yet recruiting NCT04128254 - A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE) Phase 4
Recruiting NCT05946850 - Caudal Analgesia & Anticoagulated Patient
Completed NCT05946863 - Caudal Block & Hip Fracture Surgery in Anticoagulated Patient
Recruiting NCT05545475 - Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices
Completed NCT06269302 - Comparison of the Effect of Warfarin and Direct Oral Anticoagulants
Recruiting NCT04676880 - Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy N/A
Completed NCT05224388 - Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
Completed NCT03871283 - Anticoagulation and Antiplatelet Management During Perioperative Period
Completed NCT03232398 - Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus Phase 3